Ranibizumab for High-Risk Proliferative Diabetic Retinopathy: An Exploratory Randomized Controlled Trial
Authors:
- João FigueiraJFJoão Figueira
- Rufino SilvaRSRufino Silva
- José HenriquesJHJosé Henriques
- Paulo Caldeira RosaPRPaulo Caldeira Rosa
- Inês LaínsILInês Laíns
- Pedro MeloPMPedro Melo
- Sandrina Gonçalves NunesSNSandrina Gonçalves Nunes
- José Cunha-VazJCJosé Cunha-Vaz
- 3 December 2015
- journal article
- research article
- Published by S. Karger AG in Ophthalmologica
- Vol. 235 (1) , 34-41
Abstract
Purpose: To compare the efficacy and safety of intravitreal ranibizumab (IVR) in monotherapy or associated with panretinal photocoagulation (PRP) versus conventional PRP, for high-risk proliferative diabetic retinopathy (PDR) without vitreoretinal traction. Procedures: Multicenter randomized trial, with 3 treatment arms: PRP versus IVR alone and PRP + IVR combined treatment. Follow-up was performed at months 3, 6 and 12. Results: Thirty-five subjects were randomized and 32 used for analysis. Complete regression of neovessels elsewhere occurred in 100% (PRP + IVR), 75% (IVR) and 69.2% (PRP) and for neovessels of the disk in 44.4% (PRP + IVR), 37.5% (IVR) and 30.8% (PRP). During the 1-year duration of treatment, there was no need for laser rescue treatment in IVR-treated eyes. Conclusions: This trial suggests that the use of IVR is safe and may have a beneficial effect in the treatment of eyes with high-risk PDR. Message: Ranibizumab appears to have a place in the treatment of PDR.Keywords
This publication has 21 references indexed in Scilit:
- Retinal Thickness in People with Diabetes and Minimal or No Diabetic Retinopathy: Heidelberg Spectralis Optical Coherence TomographyInvestigative Ophthalmology & Visual Science, 2012
- Triamcinolone and Bevacizumab as Adjunctive Therapies to Panretinal Photocoagulation for Proliferative Diabetic RetinopathyISRN Ophthalmology, 2012
- The Role of Angiogenesis in the Development of Proliferative Diabetic Retinopathy: Impact of Intravitreal Anti-VEGF TreatmentExperimental Diabetes Research, 2012
- Intention-to-treat concept: A reviewPerspectives in Clinical Research, 2011
- Treatment of diabetic retinopathy with anti‐VEGF drugsActa Ophthalmologica, 2010
- PANRETINAL PHOTOCOAGULATION COMBINED WITH INTRAVITREAL BEVACIZUMAB IN HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHYRetina, 2009
- Anti-VEGF Therapy in Proliferative Diabetic RetinopathyInternational Ophthalmology Clinics, 2009
- VISUAL SIDE EFFECTS OF SUCCESSFUL SCATTER LASER PHOTOCOAGULATION SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHYRetina, 2007
- INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE STUDY)Retina, 2006
- Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic RetinopathyOphthalmology, 2006